Cabaletta Bio Presents Phase 1/2 Clinical Data for rese-cel
Cabaletta Bio presented new Phase 1/2 data showing dauerable immunomodulatro-free responses in dermatomxitis and lupus nephritis patients treated with rese-cel., exhibiting favorable benefit-risk profiles supports the immunology treatments potential on the market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed